# Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

> **NCT05952453** · PHASE2 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** olaparibp, embro

## Key facts

- **NCT ID:** NCT05952453
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2028-10-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05952453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05952453, "Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05952453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*